Study of GS-2426 in Participants With Advanced Solid Tumors
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumors
In brief
The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors. The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in participants with MTAP-deleted advanced solid tumors and to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended phase II dose (RP2D).
Key facts
- Study ID
- NCT07601243
- Run by
- Gilead Sciences
- People needed
- 174
- Starts
- 2026-06-02
- Expected to finish
- 2029-01-01
- Last updated by the study team
- 2026-08-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- START Midwest — Grand Rapids, Michigan, United States (enrolling)
- START Astera, LLC — East Brunswick, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
- START San Antonio, LLC — San Antonio, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.